Ursodeoxycholic acid treatment in a rat model of cancer cachexia

A Tschirner; S von Haehling; S Palus; W Doehner; SD Anker; J Springer

doi:10.1007/s13539-011-0044-4

Ursodeoxycholic acid treatment in a rat model of cancer cachexia

A Tschirner, S von Haehling, S Palus, W Doehner, SD Anker, J Springer

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

UDCA treatment in the Yoshida hepatoma model showed a trend towards attenuation of tissue loss in animals with progressive weight loss in cancer cachexia. Tumor growth and activity indicators were not altered. Both doses of UDCA tended to reduce the mortality rates in tumor-bearing animals. Larger studies with longer follow-up are required to verify these findings.

Original language	English
Pages (from-to)	31-36
Number of pages	6
Journal	Journal of Cachexia, Sarcopenia and Muscle
Volume	3
Issue number	1
DOIs	https://doi.org/10.1007/s13539-011-0044-4
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s13539-011-0044-4

Cite this

@article{c403942c0b304033b974c8d134b775f5,

title = "Ursodeoxycholic acid treatment in a rat model of cancer cachexia",

abstract = "UDCA treatment in the Yoshida hepatoma model showed a trend towards attenuation of tissue loss in animals with progressive weight loss in cancer cachexia. Tumor growth and activity indicators were not altered. Both doses of UDCA tended to reduce the mortality rates in tumor-bearing animals. Larger studies with longer follow-up are required to verify these findings.",

author = "A Tschirner and {von Haehling}, S and S Palus and W Doehner and SD Anker and J Springer",

note = "{\textcopyright} 2012 The Authors. Published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. ",

year = "2012",

doi = "10.1007/s13539-011-0044-4",

language = "English",

volume = "3",

pages = "31--36",

journal = "Journal of Cachexia, Sarcopenia and Muscle",

issn = "2190-5991",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Ursodeoxycholic acid treatment in a rat model of cancer cachexia

AU - Tschirner, A

AU - von Haehling, S

AU - Palus, S

AU - Doehner, W

AU - Anker, SD

AU - Springer, J

N1 - © 2012 The Authors. Published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PY - 2012

Y1 - 2012

N2 - UDCA treatment in the Yoshida hepatoma model showed a trend towards attenuation of tissue loss in animals with progressive weight loss in cancer cachexia. Tumor growth and activity indicators were not altered. Both doses of UDCA tended to reduce the mortality rates in tumor-bearing animals. Larger studies with longer follow-up are required to verify these findings.

AB - UDCA treatment in the Yoshida hepatoma model showed a trend towards attenuation of tissue loss in animals with progressive weight loss in cancer cachexia. Tumor growth and activity indicators were not altered. Both doses of UDCA tended to reduce the mortality rates in tumor-bearing animals. Larger studies with longer follow-up are required to verify these findings.

U2 - 10.1007/s13539-011-0044-4

DO - 10.1007/s13539-011-0044-4

M3 - Article

SN - 2190-5991

VL - 3

SP - 31

EP - 36

JO - Journal of Cachexia, Sarcopenia and Muscle

JF - Journal of Cachexia, Sarcopenia and Muscle

IS - 1

ER -